StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Free Report) in a research note released on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.
Separately, Roth Mkm decreased their price target on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, September 23rd.
Check Out Our Latest Research Report on Aptevo Therapeutics
Aptevo Therapeutics Stock Performance
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share for the quarter, beating the consensus estimate of ($1.93) by $0.26. On average, research analysts forecast that Aptevo Therapeutics will post -2.97 earnings per share for the current fiscal year.
Institutional Trading of Aptevo Therapeutics
An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned 18.36% of Aptevo Therapeutics as of its most recent SEC filing. 8.06% of the stock is currently owned by institutional investors.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Read More
- Five stocks we like better than Aptevo Therapeutics
- How to Use the MarketBeat Excel Dividend Calculator
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Stock Splits, Do They Really Impact Investors?
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Learn Technical Analysis Skills to Master the Stock Market
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.